Whitehawk Therapeutics Reports Strong Cash Position and Clinical Pipeline Progress for FY2025

summarizeSummary

Whitehawk Therapeutics announced its full-year 2025 financial results, reporting a strong cash balance of $145.7 million, sufficient to fund operations into 2028, alongside significant advancements in its clinical oncology pipeline.

check_boxKey Events

• Strong Cash Position & Runway

  The company reported cash, cash equivalents, and short-term investments of $145.7 million as of December 31, 2025, up from $47.2 million in 2024, providing an anticipated operational runway into 2028.

• Advancing Clinical Pipeline

  Two Phase 1 trials for HWK-007 and HWK-016 are actively recruiting, with a third Investigational New Drug (IND) application for HWK-206 planned for mid-2026 and Phase 1 recruitment in Q3 2026.

• Reduced Annual Net Loss

  Full-year 2025 net loss significantly decreased to $20.6 million from $63.7 million in 2024, primarily due to an $87.3 million gain on the divestiture of an AADI Subsidiary.

• New Chief Medical Officer Appointed

  In December 2025, Dr. Margaret Dugan was appointed as Chief Medical Officer, bringing over 30 years of global oncology drug development experience.

auto_awesomeAnalysis

Whitehawk Therapeutics has reported a robust financial position with a significant cash balance that is expected to fund operations into 2028. This strong liquidity, representing approximately 77% of its current market capitalization, substantially de-risks the company's near-term financial outlook, which is critical for a clinical-stage biotech. The company also highlighted substantial progress in its oncology pipeline, with two Phase 1 trials actively recruiting and a third IND submission planned for mid-2026. While the market had some prior awareness of the cash balance, this 8-K provides the full official financial results and operational context, reinforcing the positive developments.